Dr. Eric D. Batts, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 436
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of Michigan Medical School
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MI license 4301077741
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Spectrum Health Grand Rapids, MI
- Mercy Health Saint Mary's Grand Rapids, MI
- Corewell Health Zeeland Hospital Zeeland, MI
- Holland Hospital Holland, MI
- Corewell Health Gerber Hospital Fremont, MI
Medical groups
- Cancer and Hematology Centers of Western Mi, P.c. (110 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 436
- Services billed
- 126,827
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 26,250 | 17 |
| Injection, fosaprepitant, 1 mg | 4,950 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,040 | 44 |
| Insertion of needle into vein for collection of blood sample | 1,427 | 218 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,345 | 211 |
| Injection, palonosetron hcl, 25 mcg | 1,210 | 28 |
| Blood test, comprehensive group of blood chemicals | 1,057 | 197 |
| Injection of additional new drug or substance into vein | 523 | 55 |
| Established patient office or other outpatient visit, 30-39 minutes | 502 | 220 |
| Administration of chemotherapy into vein, 1 hour or less | 391 | 68 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Holland, MI | 669 |
| Abiraterone Acetate | 498 |
| Acyclovir Other prescribers in Holland, MI | 309 |
| Anastrozole Other prescribers in Holland, MI | 297 |
| Prochlorperazine Maleate Other prescribers in Holland, MI | 167 |
| Imbruvica (ibrutinib) | 161 |
| Hydroxyurea Other prescribers in Holland, MI | 156 |
| Xtandi (enzalutamide) | 145 |
| Letrozole Other prescribers in Holland, MI | 137 |
| Levothyroxine Sodium Other prescribers in Holland, MI | 120 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 34 companies reported 78 payments worth $1,828 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $182 |
|---|---|
| GlaxoSmithKline, LLC. | $125 |
| Jazz Pharmaceuticals Inc. | $103 |
| Telix Pharmaceuticals | $100 |
| Daiichi Sankyo Inc. | $98.52 |
| Pfizer Inc. | $96.35 |
| Merck Sharp & Dohme LLC | $90.08 |
| Eisai Inc. | $86.77 |
| Food and Beverage | $1,828 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 5 companies. The companies reported $680,590 in research payments for these studies, mostly to the institutions running them.
- A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Ca…
AstraZeneca Pharmaceuticals LP - A phase 2 multi cohort open label multicenter clinical study evaluating the efficacy and safety of disitamab vedotin RC48 adc in subjects with HER2 expressing locally advanced unresectable or metastatic urothelial car…
Seagen Inc. - A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Tr…
Merck Sharp & Dohme LLC - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
AbbVie Inc. · Active, not recruiting · NCT06632951 - A phase 2 multicohort openlabel multicenter clinical study evaluating the efficacy and safety of disitamab vedotin RC48ADC alone or in combination with pembrolizumab in subjects with locallyadvanced unresectable or me…
Seagen Inc. - Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo Inc. · Recruiting · NCT07129993 - A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate …
AstraZeneca Pharmaceuticals LP - A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC IDeate-Prostate01
Merck Sharp & Dohme LLC - A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensiti…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.